Compounds > estrone
Page last updated: 2024-11-07

estrone and Uterine Prolapse

estrone has been researched along with Uterine Prolapse in 4 studies

Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.

Uterine Prolapse: Downward displacement of the UTERUS. It is classified in various degrees: in the first degree the UTERINE CERVIX is within the vaginal orifice; in the second degree the cervix is outside the orifice; in the third degree the entire uterus is outside the orifice.

Research Excerpts

ExcerptRelevanceReference
" Thirty-four postmenopausal women with uterine prolapse received either no treatment, tibolone, E(2) or E(2) + medroxyprogesterone acetate (MPA) for 21 days, or a single dose of tibolone."5.12Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate. ( Blok, LJ; Burger, CW; Hanifi-Moghaddam, P; Kloosterboer, HJ; Verheul, HA, 2007)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rahn, DD1
Good, MM1
Roshanravan, SM1
Shi, H1
Schaffer, JI1
Singh, RJ1
Word, RA1
Vardy, MD1
Lindsay, R1
Scotti, RJ1
Mikhail, M1
Richart, RM1
Nieves, J1
Zion, M1
Cosman, F1
Verheul, HA1
Blok, LJ1
Burger, CW1
Hanifi-Moghaddam, P1
Kloosterboer, HJ1
Eriksson-Mjöberg, M1
Olund, A1
Carlström, K1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Preoperative Locally Applied Oestrogen in Postmenopausal Women With Pelvic Organ Prolapse: Changes in Subjective and Objective Outcome - a Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study[NCT03779633]Phase 4120 participants (Actual)Interventional2017-02-02Completed
Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor[NCT01778985]Phase 430 participants (Actual)Interventional2012-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Estimated Blood Loss

Intraoperative estimated blood loss (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

InterventionmL (Mean)
Premarin285
Placebo285

hCOL1A1, Per-Protocol

Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionratio (Median)
Premarin2.19
Placebo0.37

hCOL3, (Per-Protocol)

Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionratio (Median)
Premarin.92
Placebo.37

LOXL1 (Per-Protocol)

Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionratio (Mean)
Premarin.64
Placebo.69

Lysyl Oxidase (LOX) (Per-Protocol)

Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionratio (Mean)
Premarin.74
Placebo.51

Serum Estradiol Levels, Baseline

(NCT01778985)
Timeframe: Baseline

Interventionpg/mL (Mean)
Premarin11.1
Placebo8.4

Serum Estradiol Levels, Surgery

(NCT01778985)
Timeframe: Time of surgery

Interventionpg/mL (Mean)
Premarin7.8
Placebo11.6

Serum Estrone Levels, Baseline

(NCT01778985)
Timeframe: Baseline

Interventionpg/mL (Mean)
Premarin18.0
Placebo18.5

Serum Estrone Levels, Surgery

(NCT01778985)
Timeframe: Time of surgery

Interventionpg/mL (Mean)
Premarin22.8
Placebo24.9

TGFB1 (Per-Protocol)

Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionratio (Mean)
Premarin.61
Placebo.81

Total Collagen Content in Vaginal Muscularis, (Per-Protocol)

Will assess hydroxy-proline assays as index of amount of collagen (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionmg collagen per mg muscularis wet weight (Mean)
Premarin302.6
Placebo94.86

Tropoelastin (Per-Protocol)

Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionratio (Mean)
Premarin.78
Placebo.69

Vaginal Wall Composition: Epithelium (Intention to Treat)

Will assess vaginal wall histology - thicknesses of epithelium (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionmicrons (Mean)
Premarin413.9
Placebo314.1

Vaginal Wall Composition: Epithelium (Per-Protocol)

Will assess vaginal wall histology - thicknesses of epithelium (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionmicrons (Mean)
Premarin550.5
Placebo314.1

Vaginal Wall Composition: Lamina Propria (Intention to Treat)

Will assess vaginal wall histology - thickness of lamina propria. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionmicrons (Mean)
Premarin1042.3
Placebo895.1

Vaginal Wall Composition: Lamina Propria (Per-Protocol)

Will assess vaginal wall histology - thickness of lamina propria (NCT01778985)
Timeframe: Time of surgery, i.e. 6-8 weeks of intervention

Interventionmicrons (Mean)
Premarin1133.4
Placebo895.1

Vaginal Wall Composition: Muscularis (Intention to Treat)

Will assess vaginal wall histology - thicknesses of muscularis (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionmicrons (Mean)
Premarin5670.4
Placebo2807.1

Vaginal Wall Composition: Muscularis (Per-Protocol)

Will assess vaginal wall histology - thicknesses of muscularis (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

Interventionmicrons (Mean)
Premarin7570.7
Placebo2807.1

Vaginal Wall Degradative Activity, Mucosa, MMP-9

Will assess zymograms for total matrix metalloprotease (MMP) 9 activity (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

InterventionRelative Units/mg protein (Mean)
Premarin8.97
Placebo56.73

Vaginal Wall Degradative Activity, Muscularis, MMP-9

Will assess zymograms for total matrix metalloprotease (MMP) 9 activity (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention

InterventionRelative Units/mg protein (Mean)
Premarin37.03
Placebo132.34

Trials

3 trials available for estrone and Uterine Prolapse

ArticleYear
Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial.
    The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:10

    Topics: Administration, Intravaginal; Biopsy; Collagen; Collagenases; Double-Blind Method; Estradiol; Estrog

2014
Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial.
    The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:10

    Topics: Administration, Intravaginal; Biopsy; Collagen; Collagenases; Double-Blind Method; Estradiol; Estrog

2014
Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial.
    The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:10

    Topics: Administration, Intravaginal; Biopsy; Collagen; Collagenases; Double-Blind Method; Estradiol; Estrog

2014
Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial.
    The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:10

    Topics: Administration, Intravaginal; Biopsy; Collagen; Collagenases; Double-Blind Method; Estradiol; Estrog

2014
Short-term urogenital effects of raloxifene, tamoxifen, and estrogen.
    American journal of obstetrics and gynecology, 2003, Volume: 189, Issue:1

    Topics: Aged; Atrophy; Double-Blind Method; Estradiol; Estrogens; Estrogens, Conjugated (USP); Estrone; Fema

2003
Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate.
    Reproductive sciences (Thousand Oaks, Calif.), 2007, Volume: 14, Issue:2

    Topics: Aged; Estradiol; Estrone; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Myometrium; Norp

2007

Other Studies

1 other study available for estrone and Uterine Prolapse

ArticleYear
Hormonal patterns in postmenopausal women during gynecological surgery.
    Gynecologic and obstetric investigation, 1997, Volume: 43, Issue:1

    Topics: 17-alpha-Hydroxyprogesterone; Aged; Analgesics, Opioid; Androstenedione; Anesthesia, Epidural; Anest

1997